Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Neuro-feedback Therapy for Treating Tinnitus (TNTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03773926
Recruitment Status : Recruiting
First Posted : December 12, 2018
Last Update Posted : December 12, 2018
Sponsor:
Collaborator:
University Hospital, Toulouse
Information provided by (Responsible Party):
Zeta Technologies

Brief Summary:
Neuro-feedback for treating tinnitus seem to be a promising approach to help people suffering from chronic tinnitus. The past studies on this approach suffered interindividual variability in their results. The investigators' current hypothesis is that the variability of the results is the consequences of two possible flaws: lack of appropriate patient selection and lack of support of the patient during the therapy. This study is aimed at testing these hypotheses.

Condition or disease Intervention/treatment Phase
Tinnitus Hearing Loss Device: Neuro-feedback therapy Not Applicable

Detailed Description:

Many individuals with tinnitus have abnormal oscillatory brain activity in their temporal areas (Weisz et al. (2005), Schlee et al. (2014)). Led by this finding, attempts to normalize such localized pathological activity by neuro-feedback techniques have been tested (Dohrmann et al. (2007), Gütenspenger et al. (2017)). These attempts highlighted interindividual variability that can be explained by lack of selection of the patient population and lack of guidance through the therapy. The present study is aimed at addressing these issues by choosing more selectively a patient subpopulation (tinnitus associated with moderate hearing loss) and by implementing a guidance interface during the treatment.

The therapy will consist of 10 neuro-feedback training sessions of 29 minutes over 5 weeks. Each session will be composed of 6 blocks of 3 min in which the patient will be incited to practise a specific cognitive strategy (mental exercise such as "think to a music you like") and resting state measurements.

Each patient who has been recruited to fit our inclusion and non-inclusion criteria will first go through a clinical assessment of his initial judgment criteria metrics. Then subjects will go through the 5-week training and then will be evaluated on the same criteria just after the end of the therapy and at 3 months after the end of it.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Intervention Model Description: An efficiency multicentric pilot study on a targeted population for development and use of Neuro-feedback therapy for treating tinnitus.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Neuro-feedback Therapy for Treating Tinnitus : Efficacy Pilot Study on a Targeted Population
Actual Study Start Date : May 28, 2018
Estimated Primary Completion Date : January 15, 2019
Estimated Study Completion Date : January 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tinnitus

Arm Intervention/treatment
Experimental: Neuro-feedback therapy

EEG headset is placed on the patients head and the electrodes record the brain activity from F3, F4, FC1 and FC2 (on the 10-10 international localization system of EEG electrodes) and generate feedback.

Each session is composed of 6 blocks of 3 minutes in which the patient is incited to practice a specific cognitive strategy. During the 4 first session, 8 strategies are explored. Then through the therapy, the best cognitive strategies are gradually selected through an automatized process taking in account objective performances and subjective feedback.

Device: Neuro-feedback therapy
The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.




Primary Outcome Measures :
  1. Comparison of initial and final Tinnitus Handicap Inventory (THI) distributions [ Time Frame: Comparison of initial and final THI before and after treatment for a Time frame of 5 weeks. ]
    This primary outcome measure denotes the evolution of the deterioration of the quality of life of patients due to tinnitus. THI is a questionnaire composed of 25 questions each with 3 response options converting in 0, 2, and 4 points scoring, making it a scale from 0 to 100 points.


Secondary Outcome Measures :
  1. Comparison of initial and final Visual Analog Scale (VAS) distributions [ Time Frame: Comparison of initial and final VAS before and after treatment for a Time frame of 5 weeks. ]
    The secondary outcome measure denotes the evolution of the intensity of tinnitus and the disturbance associated measured by two scales. First the Visual Analog Scale (VAS) for intensity of Tinnitus enables the patient to rate his tinnitus intensity with integers values between 1 to 10 (included). Second, the Visual Analog Scale (VAS) for Tinnitus associated disturbance enables the patient to rate his tinnitus associated diturbance with integers values between 1 to 10 (included). For both scales, a high value (near 10) indicates a high gravity of the symptom, regarding either its intensity or its associated disturbance, while low values (near 1), indicate lighter impact of the symptom regarding its intensity or its associated disturbance. The scores are assessed subjectively by the patient when asked.

  2. Evolution of Tinnitus Handicap Inventory (THI) and Visual Analog Scales (VAS) on tinnitus intensity and associated disturbance 3 month after the treatment [ Time Frame: 3 months after the end of the 5 week treatment ]
    Evaluation of maintenance of effects perceived 3 months after the treatment. The THI and the VAS scales are used similarly to the precedent outcome measures. THI is a questionnaire composed of 25 questions each with 3 response options converting in 0, 2, and 4 points scoring, making it a scale from 0 to 100 points. the Visual Analog Scale (VAS) for intensity of Tinnitus enables the patient to rate his tinnitus intensity with integers values between 1 to 10 (included). The Visual Analog Scale (VAS) for Tinnitus associated disturbance enables the patient to rate his tinnitus associated diturbance with integers values between 1 to 10 (included). For both visual analog scales, a high value (near 10) indicates a high gravity of the symptom, regarding either its intensity or its associated disturbance, while low values (near 1), indicate lighter impact of the symptom regarding its intensity or its associated disturbance.

  3. Side effects [ Time Frame: The total duration of the study ]
    Evaluation of potential side effects during the study. At each session patients will be asked if they want to declare any side effects they believe to be related to the treatment.

  4. Evolution of pathological attention level (BAHIA) standing for (in french) Biphasique, Acouphène, Hyperacousie, Insensibilité de la face et Autres sensations. [ Time Frame: Comparison of initial and final BAHIA before and after treatment for a Time frame of 5 weeks. ]
    Evaluation of the proportion of daily time that the patient reports experiencing and being disturbed by his tinnitus through 4 questions.

  5. Correlation of the electrophysiological measurements and the THI/VAS measurements [ Time Frame: Over the 5 weeks of treatment ]
    Correlation between the plastic effects induced by therapy on electrophysiological measurements and the assessment of the severity of tinnitus through the THI/VAS.

  6. Evolution of the THI, BAHIA, and VAS scores, expressed as a percentage of the initial value [ Time Frame: Comparison of initial and final measurements before and after treatment for a Time frame of 5 weeks. ]
    Evolution of the precedent quoted measures before and after treatment measured as percentages of the initial value (proportion of evolution of the THI, VAS and BAHIA measurements).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria :

  • Age > 18
  • Social security affiliation
  • Permanent, non-fluctuation, high pitch, bilateral or assimilated, tinnitus
  • Mean value of the VAS at least at 6 between the intensity and the disturbance criteria at the recruitment interview.
  • THI score superior or equal to 40 at the recruitment interview
  • Written consent to the protocol
  • Associated hearing-loss characterized by :
  • mean value of the hearing threshold loss for the 250, 500 and 1000 Hz thresholds strictly under 25 dB (deciBel).
  • at least one hearing threshold among the 2000, 4000, 6000 and 8000 Hz with at least 30 dB of hearing loss.
  • mean value of the hearing threshold loss for the 2000, 4000, 6000 and 8000 Hz thresholds strictly under 70 dB.

Exclusion Criteria:

  • Subjects under legal protection (guardianship, trusteeship or judicial protection)
  • Notable cognitive disability impeding to understanding or performing the cognitive tasks
  • Meniere's disease, chronic or serous otitis, acoustic neuroma
  • Pulsatile tinnitus, somatosensorial tinnitus
  • Epilepsy
  • No antidepressant or anti-epileptic drug treatment
  • DET (DETresse) questionnaire (measure of tinnitus associated distress) above or equal to 40
  • Use of a sound generator during the therapy
  • Pregnancy or breastfeeding
  • Inability to wear the electrodes headset of the neuro-feedback device

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03773926


Contacts
Layout table for location contacts
Contact: Alain LONDERO 05 61 77 21 19 Alain.londero@aphp.fr
Contact: Renaud SIMEON 01 40 19 36 61 r.simeon@ch-bry.org

Locations
Layout table for location information
France
Audika Research Center Recruiting
Paris, Ile De France, France, 75005
Contact: ROBIN GUILLARD    0033642480836    r@zetatech.fr   
Contact: THOMAS CERVONI    0033638895203    t@zetatech.fr   
Principal Investigator: ALAIN LONDERO         
Sub-Investigator: RENAUD SIMEON         
Purpan University hospital Recruiting
Toulouse, Languedoc-Roussillon-Midi-Pyrénées, France, 31300
Contact: Jonathan SCHMUTZ    0033634390378    j@zetatech.fr   
Contact: Agnès AGASSE    00335 61 77 77 70      
Principal Investigator: Marie-Josée FRAYSSE         
Sponsors and Collaborators
Zeta Technologies
University Hospital, Toulouse
Investigators
Layout table for investigator information
Principal Investigator: Marie-Josée FRAYSSE University Hospital, Toulouse

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Zeta Technologies
ClinicalTrials.gov Identifier: NCT03773926    
Other Study ID Numbers: 2018-A00604-51
First Posted: December 12, 2018    Key Record Dates
Last Update Posted: December 12, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zeta Technologies:
Tinnitus
Neuro-feedback
Male
Female
Tinnitus Handicap Inventory
Additional relevant MeSH terms:
Layout table for MeSH terms
Hearing Loss
Tinnitus
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms